Developing a prognostic model for biomedical applications typically requires mapping an
individual’s set of covariates to a measure of the risk that he or she may experience the event …

Because other coronaviruses enter the cells by binding to dipeptidyl‐peptidase‐4 (DPP‐4),
it has been speculated that DPP‐4 inhibitors (DPP‐4is) may exert an activity against severe …

Introduction Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1
receptor agonists (GLP-1RA) protect type 2 diabetic (T2D) patients from cardiovascular …

People with diabetes require lifelong access to healthcare services to delay the onset of
complications. Their disease management processes generate great volumes of data across …

Background and aims Diabetes can often remain undiagnosed or unregistered in administrative
databases long after its onset, even when laboratory test results meet diagnostic criteria. …

Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder
characterised by the progressive loss of motor neurons in the brain and spinal cord. The fact that …

Background Cardiovascular outcome trials in high-risk patients showed that some GLP-1
receptor agonists (GLP-1RA), but not dipeptidyl-peptidase-4 inhibitors (DPP-4i), can prevent …

ALS is a severe chronic disease characterized by a progressive but variable impairment of
neurological functions, characterized by high heterogeneity both in presentation features and …

Amyotrophic Lateral Sclerosis (ALS) is a severe chronic disease characterized by progressive
or alternate impairment of neurological functions, characterized by high heterogeneity …

Background: Many glycemic variability (GV) indices exist in the literature. In previous works,
we demonstrated that a set of GV indices, extracted from continuous glucose monitoring (…